Molecular Human Reproduction, Vol. 5, No. 11, 995-1002,
November 1999
© 1999 European Society of Human Reproduction and Embryology
Molecular endocrinology |
Regulation of sulphotransferase expression in the endometrium during the menstrual cycle, by oral contraceptives and during early pregnancy
1 Departments of Molecular & Cellular Pathology and 2 Obstetrics & Gynaecology, University of Dundee, Dundee DD1 9SY, UK and 3 Department of Pharmacology & Toxicology, University of Alabama at Birmingham, Birmingham, AL 35294, USA
Abstract
The endometrium plays a key role in reproduction, and this function is tightly regulated by endogenous and xenobiotic steroids. Sulphation, catalysed by members of the sulphotransferase (SULT) enzyme family, is a major deactivating mechanism for steroid hormones and we have investigated the expression and regulation in vivo of SULT in the human endometrium. In the normal cycling endometrium, expression of the phenol sulphotransferases SULT1A1 and SULT1A3 and the oestrogen sulphotransferase SULT1E1 were observed, with SULT1A1 and SULT1E1 expression being higher in the luteal phase than in the follicular phase. No expression of the hydroxysteroid sulphotransferase SULT2A1 was detected at any time in the endometrium. In endometrium from women taking the combined oral contraceptive pill (OCP), SULT1E1 expression was virtually absent, and SULT1A1 expression was substantially reduced. Similarly, in early pregnancy (i.e. first trimester) endometrium, SULT1E1 expression was absent, although SULT1A1 and SULT1A3 expression were unaffected. Our results with normal endometrium support in-vitro data showing that SULT1E1 expression is regulated by progesterone. However, the data obtained from OCP and early pregnancy endometrium suggest that factors other than the concentration of circulating progesterone are involved in the regulation of the expression of this important enzyme in the endometrium.
endometrium/oestrogens/sulphation/sulphotransferase
Notes
4 Present Address: Prince Henry's Institute of Medical Research, PO Box 5152, Clayton, Victoria 3168, Australia
5 To whom correspondence should be addressed at: Department of Molecular & Cellular Pathology, University of Dundee, Ninewells Hospital & Medical School, Dundee DD1 9SY, UK
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  H. Andersson, M. Helmestam, A. Zebrowska, M. Olovsson, and E. Brittebo Tamoxifen-Induced Adduct Formation and Cell Stress in Human Endometrial Glands Drug Metab. Dispos., January 1, 2010; 38(1): 200 - 207. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. Riches, E. L. Stanley, J. C. Bloomer, and M. W. H. Coughtrie Quantitative Evaluation of the Expression and Activity of Five Major Sulfotransferases (SULTs) in Human Tissues: The SULT "Pie" Drug Metab. Dispos., November 1, 2009; 37(11): 2255 - 2261. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Gershon, A. Hourvitz, S. Reikhav, E. Maman, and N. Dekel Low expression of COX-2, reduced cumulus expansion, and impaired ovulation in SULT1E1-deficient mice FASEB J, June 1, 2007; 21(8): 1893 - 1901. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Y. Kim, Y. R. S. Laxmi, N. Suzuki, K. Ogura, T. Watabe, M. W. Duffel, and S. Shibutani FORMATION OF TAMOXIFEN-DNA ADDUCTS VIA O-SULFONATION, NOT O-ACETYLATION, OF {alpha}-HYDROXYTAMOXIFEN IN RAT AND HUMAN LIVERS Drug Metab. Dispos., November 1, 2005; 33(11): 1673 - 1678. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. H. Phillips, A. Hewer, M. R. Osborne, K. J. Cole, C. Churchill, and V. M. Arlt Organ specificity of DNA adduct formation by tamoxifen and {alpha}-hydroxytamoxifen in the rat: implications for understanding the mechanism(s) of tamoxifen carcinogenicity and for human risk assessment Mutagenesis, July 1, 2005; 20(4): 297 - 303. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Hempel, H. Wang, E. L. LeCluyse, M. E. McManus, and M. Negishi The Human Sulfotransferase SULT1A1 Gene Is Regulated in a Synergistic Manner by Sp1 and GA Binding Protein Mol. Pharmacol., December 1, 2004; 66(6): 1690 - 1701. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Taskinen, B. T. Ethell, P. Pihlavisto, A. M. Hood, B. Burchell, and M. W. H. Coughtrie CONJUGATION OF CATECHOLS BY RECOMBINANT HUMAN SULFOTRANSFERASES, UDP-GLUCURONOSYLTRANSFERASES, AND SOLUBLE CATECHOL O-METHYLTRANSFERASE: STRUCTURE-CONJUGATION RELATIONSHIPS AND PREDICTIVE MODELS Drug Metab. Dispos., September 1, 2003; 31(9): 1187 - 1197. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. C. Poirier and L. J. Schild The Genotoxicity of Tamoxifen: Extent and Consequences, Kona, Hawaii, January 23, 2003 Mutagenesis, July 1, 2003; 18(4): 395 - 399. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Miki, T. Nakata, T. Suzuki, A. D. Darnel, T. Moriya, C. Kaneko, K. Hidaka, Y. Shiotsu, H. Kusaka, and H. Sasano Systemic Distribution of Steroid Sulfatase and Estrogen Sulfotransferase in Human Adult and Fetal Tissues J. Clin. Endocrinol. Metab., December 1, 2002; 87(12): 5760 - 5768. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Sonoda, W. Xie, J. M. Rosenfeld, J. L. Barwick, P. S. Guzelian, and R. M. Evans Regulation of a xenobiotic sulfonation cascade by nuclear pregnane X receptor (PXR) PNAS, October 15, 2002; 99(21): 13801 - 13806. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. H. A. Kester, S. Bulduk, H. van Toor, D. Tibboel, W. Meinl, H. Glatt, C. N. Falany, M. W. H. Coughtrie, A. G. Schuur, A. Brouwer, et al. Potent Inhibition of Estrogen Sulfotransferase by Hydroxylated Metabolites of Polyhalogenated Aromatic Hydrocarbons Reveals Alternative Mechanism for Estrogenic Activity of Endocrine Disrupters J. Clin. Endocrinol. Metab., March 1, 2002; 87(3): 1142 - 1150. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. L. Stanley, R. Hume, T. J. Visser, and M. W. H. Coughtrie Differential Expression of Sulfotransferase Enzymes Involved in Thyroid Hormone Metabolism during Human Placental Development J. Clin. Endocrinol. Metab., December 1, 2001; 86(12): 5944 - 5955. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. W. H. Coughtrie and L. E. Johnston Interactions between Dietary Chemicals and Human Sulfotransferases{---}Molecular Mechanisms and Clinical Significance Drug Metab. Dispos., April 1, 2001; 29(4): 522 - 528. [Abstract] [Full Text]
|
|
|
|
|
|
J. Kitawaki, H. Koshiba, H. Ishihara, I. Kusuki, K. Tsukamoto, and H. Honjo Progesterone Induction of 17{beta}-Hydroxysteroid Dehydrogenase Type 2 during the Secretory Phase Occurs in the Endometrium of Estrogen-Dependent Benign Diseases But Not in Normal Endometrium J. Clin. Endocrinol. Metab., September 1, 2000; 85(9): 3292 - 3296. [Abstract] [Full Text]
|
|